Literature DB >> 28028585

Effects of a primary care intervention to improve the quality of zolpidem prescriptions in elderly patients.

Rocío López-Sepúlveda1, María Ángeles García Lirola2, Esther Espínola García1, Salvadora Martín Sances1, Sonia Anaya Ordóñez1, José María Jurado Martínez1, José Cabeza Barrera3.   

Abstract

PURPOSE: The objective of this study was to measure the impact of an intervention on the prescription habits of general practitioners (GPs) in order to improve the quality of zolpidem prescriptions in patients aged 75 or older.
METHODS: A prospective multicentric non-randomized trial was performed in the Metropolitan Granada Primary Healthcare Area (Andalusian Public Healthcare Service, Spain), which serves a total population of approximately 675,000 inhabitants. All health centers volunteering to participate in the trial were included. The intervention consisted of training sessions, individualized feedback, clinical information, and financial incentives. A daily dose over 5 mg was considered non-safe. Reduction in non-safe prescriptions of zolpidem in the elderly population became a quality prescribing indicator in a pay-for-performance scheme.
RESULTS: Statistically significant differences versus baseline were found between the intervention and control groups in mean zolpidem prescription prevalence (28.5 vs. 37.5‰, respectively; p = 0.008) and mean non-safe zolpidem prescription prevalence (16.5 vs. 34.2‰, respectively; p < 0.001). At the end of the study period, the total number of non-safe prescriptions was 1309, 35% lower versus baseline, with a significant difference of p < 0.001; the number in the intervention (510 vs. 1118; p < 0.001) and control (799 vs. 893; p = 0.0064) groups was also significantly lower, with a significantly greater percentage reduction in the intervention group (54.4 vs. 10.5%, p < 0.001).
CONCLUSION: The quality prescribing indicator in our area was improved by the intervention developed. Further studies that include an intervention group of GPs who receive no financial incentive are required to evaluate the relative importance of an economic reward in achieving this improvement.

Entities:  

Keywords:  Elderly; General practitioners; Physician incentive plans; Physician’s practice pattern; Zolpidem

Mesh:

Substances:

Year:  2016        PMID: 28028585     DOI: 10.1007/s00228-016-2180-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.

Authors:  Rikje Ruiter; Loes E Visser; Myrthe P P van Herk-Sukel; Petronella H Geelhoed-Duijvestijn; Sandra de Bie; Sabine M J M Straus; Peter G M Mol; Silvana A Romio; Ron M C Herings; Bruno H Ch Stricker
Journal:  Drug Saf       Date:  2012-06-01       Impact factor: 5.606

2.  American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.

Authors: 
Journal:  J Am Geriatr Soc       Date:  2015-10-08       Impact factor: 5.562

3.  Safety analysis of zolpidem in elderly subjects 80 years of age or older: adverse event monitoring in Japanese subjects.

Authors:  Ayami Kajiwara; Masato Yamamura; Motoji Murase; Haruo Koda; Seisuke Hirota; Tadao Ishizuka; Kazunori Morita; Kentaro Oniki; Junji Saruwatari; Kazuko Nakagawa
Journal:  Aging Ment Health       Date:  2015-04-14       Impact factor: 3.658

4.  Re: American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults.

Authors:  Tomas L Griebling
Journal:  J Urol       Date:  2012-08-16       Impact factor: 7.450

Review 5.  Hypnotics in insomnia: the experience of zolpidem.

Authors:  James MacFarlane; Charles M Morin; Jacques Montplaisir
Journal:  Clin Ther       Date:  2014-11-19       Impact factor: 3.393

6.  Benzodiazepine and sedative-hypnotic use among older seriously Ill veterans: choosing wisely?

Authors:  Melissa M Garrido; Holly G Prigerson; Joan D Penrod; Shatice C Jones; Kenneth S Boockvar
Journal:  Clin Ther       Date:  2014-11-04       Impact factor: 3.393

7.  Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone.

Authors:  Ingrid Leal; Silvana A Romio; Martijn Schuemie; Alessandro Oteri; Miriam Sturkenboom; Gianluca Trifirò
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

Review 8.  The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents.

Authors:  David J Sanger
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

9.  Impact of a US Food and Drug Administration Drug Safety Communication on Zolpidem Dosing: An Observational Retrospective Cohort.

Authors:  Jonathan L Harward; Valerie B Clinard; Michael R Jiroutek; Beverly H Lingerfeldt; Andrew J Muzyk
Journal:  Prim Care Companion CNS Disord       Date:  2015-03-05

10.  Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.

Authors:  Vishal Ahuja; Min-Woong Sohn; John R Birge; Chad Syverson; Elly Budiman-Mak; Nicholas Emanuele; Jennifer M Cooper; Elbert S Huang
Journal:  J Manag Care Spec Pharm       Date:  2015-12
View more
  1 in total

1.  Reducing prescribing of benzodiazepines in older adults: a comparison of four physician-focused interventions by a medical regulatory authority.

Authors:  Nigel Ashworth; Nicole Kain; Delaney Wiebe; Nancy Hernandez-Ceron; Ed Jess; Karen Mazurek
Journal:  BMC Fam Pract       Date:  2021-04-08       Impact factor: 2.497

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.